ACS chemical neuroscience molecule spotlight on RG1678

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.

Original languageEnglish (US)
Pages (from-to)685-686
Number of pages2
JournalACS Chemical Neuroscience
Volume2
Issue number12
DOIs
StatePublished - Dec 21 2011

Fingerprint

Neurosciences
Glycine Plasma Membrane Transport Proteins
Molecules
Antipsychotic Agents
Schizophrenia
(4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone

Keywords

  • GlyT1
  • RG1678
  • Schizophrenia
  • glycine transporter-1 inhibitor
  • negative symptoms

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

ACS chemical neuroscience molecule spotlight on RG1678. / Hopkins, Corey R.

In: ACS Chemical Neuroscience, Vol. 2, No. 12, 21.12.2011, p. 685-686.

Research output: Contribution to journalArticle

@article{efd2f4694d8345bca92747efe98ff428,
title = "ACS chemical neuroscience molecule spotlight on RG1678",
abstract = "RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.",
keywords = "GlyT1, RG1678, Schizophrenia, glycine transporter-1 inhibitor, negative symptoms",
author = "Hopkins, {Corey R.}",
year = "2011",
month = "12",
day = "21",
doi = "10.1021/cn200108z",
language = "English (US)",
volume = "2",
pages = "685--686",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on RG1678

AU - Hopkins, Corey R.

PY - 2011/12/21

Y1 - 2011/12/21

N2 - RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.

AB - RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.

KW - GlyT1

KW - RG1678

KW - Schizophrenia

KW - glycine transporter-1 inhibitor

KW - negative symptoms

UR - http://www.scopus.com/inward/record.url?scp=84555177567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84555177567&partnerID=8YFLogxK

U2 - 10.1021/cn200108z

DO - 10.1021/cn200108z

M3 - Article

C2 - 22860161

AN - SCOPUS:84555177567

VL - 2

SP - 685

EP - 686

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 12

ER -